Tyruko 유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Nurofen Zatoki 200 mg + 30 mg Tabletki powlekane 폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

nurofen zatoki 200 mg + 30 mg tabletki powlekane

reckitt benckiser (poland) s.a. - ibuprofenum + pseudoephedrini hydrochloridum - tabletki powlekane - 200 mg + 30 mg